Radiotherapy research changes standard clinical practice and improves survival for patients with small-cell lung cancer

Impact: Health and wellbeing

Narrative

We led and co-led two international, phase III radiotherapy trials in small-cell lung cancer (SCLC), which changed and standardised routine clinical practice and improved patient survival.
The CONVERT trial led to greater standardisation of chemo-radiotherapy treatment for limited-stage disease and the adoption of an optimised treatment regimen in UK, European and US guidance. The trial also showed that chemo-radiotherapy was a feasible treatment option for patients over 70 years who were previously under-treated.
Following the CREST trial, the number of centres offering thoracic radiotherapy in seven surveyed European countries, including UK, rose from 25% to 81%. Local thoracic radiotherapy treatment has been adopted in UK, European, US and Australian clinical guidelines.
Impact date1 Aug 2013 → 31 Dec 2020
Category of impactHealth and wellbeing
Impact levelAdoption

Research Beacons, Institutes and Platforms

  • Cancer
  • Manchester Cancer Research Centre

Documents & Links

Related content